Style | Citing Format |
---|---|
MLA | Cheng Y, et al.. "Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation." RSC Advances, vol. 13, no. 27, 2023, pp. 18450-18460. |
APA | Cheng Y, Farasati Far B, Jahanbakhshi M, Bahrami S, Tamimi P, Sedaghat M, Ghazizadeha E (2023). Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation. RSC Advances, 13(27), 18450-18460. |
Chicago | Cheng Y, Farasati Far B, Jahanbakhshi M, Bahrami S, Tamimi P, Sedaghat M, Ghazizadeha E. "Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation." RSC Advances 13, no. 27 (2023): 18450-18460. |
Harvard | Cheng Y et al. (2023) 'Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation', RSC Advances, 13(27), pp. 18450-18460. |
Vancouver | Cheng Y, Farasati Far B, Jahanbakhshi M, Bahrami S, Tamimi P, Sedaghat M, et al.. Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation. RSC Advances. 2023;13(27):18450-18460. |
BibTex | @article{ author = {Cheng Y and Farasati Far B and Jahanbakhshi M and Bahrami S and Tamimi P and Sedaghat M and Ghazizadeha E}, title = {Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation}, journal = {RSC Advances}, volume = {13}, number = {27}, pages = {18450-18460}, year = {2023} } |
RIS | TY - JOUR AU - Cheng Y AU - Farasati Far B AU - Jahanbakhshi M AU - Bahrami S AU - Tamimi P AU - Sedaghat M AU - Ghazizadeha E TI - Exploring the Potential of a Polyvinyl Alcohol/Chitosan-Based Nanofibrous Matrix for Erythromycin Delivery: Fabrication, in Vitro and in Vivo Evaluation JO - RSC Advances VL - 13 IS - 27 SP - 18450 EP - 18460 PY - 2023 ER - |